Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma
Top Cited Papers
- 8 October 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Medicine
- Vol. 24 (11), 1649-1654
- https://doi.org/10.1038/s41591-018-0197-1
Abstract
Preclinical studies suggest that treatment with neoadjuvant immune checkpoint blockade is associated with enhanced survival and antigen-specific T cell responses compared with adjuvant treatment1; however, optimal regimens have not been defined. Here we report results from a randomized phase 2 study of neoadjuvant nivolumab versus combined ipilimumab with nivolumab in 23 patients with high-risk resectable melanoma (NCT02519322). RECIST overall response rates (ORR), pathologic complete response rates (pCR), treatment-related adverse events (trAEs) and immune correlates of response were assessed. Treatment with combined ipilimumab and nivolumab yielded high response rates (RECIST ORR 73%, pCR 45%) but substantial toxicity (73% grade 3 trAEs), whereas treatment with nivolumab monotherapy yielded modest responses (ORR 25%, pCR 25%) and low toxicity (8% grade 3 trAEs). Immune correlates of response were identified, demonstrating higher lymphoid infiltrates in responders to both therapies and a more clonal and diverse T cell infiltrate in responders to nivolumab monotherapy. These results describe the feasibility of neoadjuvant immune checkpoint blockade in melanoma and emphasize the need for additional studies to optimize treatment regimens and to validate putative biomarkers.Keywords
This publication has 27 references indexed in Scilit:
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Integrating mapping-, assembly- and haplotype-based approaches for calling variants in clinical sequencing applicationsNature Genetics, 2014
- Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer PatientsScience Translational Medicine, 2014
- Nivolumab plus Ipilimumab in Advanced MelanomaThe New England Journal of Medicine, 2013
- Sensitive detection of somatic point mutations in impure and heterogeneous cancer samplesNature Biotechnology, 2013
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerThe New England Journal of Medicine, 2012
- A framework for variation discovery and genotyping using next-generation DNA sequencing dataNature Genetics, 2011
- Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short readsBioinformatics, 2009
- Fast and accurate short read alignment with Burrows–Wheeler transformBioinformatics, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009